Fluconazole Dosing for Candida UTI and Cutaneous Candidiasis
For uncomplicated Candida urinary tract infections (cystitis), use oral fluconazole 200 mg daily for 2 weeks; for cutaneous candidiasis, topical antifungals are first-line, but if systemic therapy is needed, use fluconazole 100-200 mg daily for 7-14 days depending on severity.
Candida Urinary Tract Infections
Cystitis (Lower UTI)
The 2016 IDSA guidelines provide clear direction for fluconazole-susceptible organisms 1:
- Dose: Fluconazole 200 mg (3 mg/kg) orally daily
- Duration: 2 weeks (strong recommendation, moderate-quality evidence)
- Critical step: Remove indwelling bladder catheter if present (strong recommendation)
The FDA label supports dosing of 50-200 mg daily for Candida UTI 2, though the IDSA guideline's 200 mg dose represents the current standard. Recent research from 2025 suggests shorter durations may be adequate—a median of 7 days showed equivalent clinical success (93.1%) compared to 14 days (93.3%) 3—but I recommend adhering to the 14-day guideline duration until more robust prospective data emerge, particularly given the low-quality evidence base.
Pyelonephritis (Upper UTI)
For ascending infection 1:
- Dose: Fluconazole 200-400 mg (3-6 mg/kg) orally daily
- Duration: 2 weeks (strong recommendation, low-quality evidence)
- Address obstruction: Eliminate any urinary tract obstruction (strong recommendation)
Important Caveats
Asymptomatic candiduria does NOT require treatment unless the patient is 1:
- Neutropenic
- Very low-birth-weight infant (<1500 g)
- Undergoing urologic manipulation (give fluconazole 400 mg daily for several days before and after procedure)
For fluconazole-resistant species 1:
- C. glabrata: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days
- C. krusei: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days
Cutaneous Candidiasis
The IDSA guidelines address mucocutaneous candidiasis but don't specifically detail dosing for simple cutaneous infections. Based on the oropharyngeal candidiasis recommendations as a proxy for mucocutaneous disease 1:
Mild Disease
- First-line: Topical antifungals (clotrimazole, miconazole, nystatin)
- If systemic therapy needed: Fluconazole 100 mg daily for 7-14 days
Moderate to Severe Disease
- Dose: Fluconazole 100-200 mg orally daily
- Duration: 7-14 days (strong recommendation, high-quality evidence) 1
Research supports once-weekly fluconazole 150 mg for dermatophyte infections (tinea corporis/cruris), with a mean of 2.6 doses achieving 92% clinical cure 4. However, for Candida cutaneous infections specifically, daily dosing is more appropriate given the different pathogen and infection characteristics.
Clinical Pearls
Absorption considerations: Fluconazole absorption is excellent (>93% bioavailability) and unaffected by food, gastric pH, or gastrointestinal resection 5. This makes it highly reliable for oral therapy.
Renal dosing: For creatinine clearance ≤50 mL/min, reduce dose by 50% after a standard loading dose 2. Hemodialysis patients should receive 100% of the recommended dose after each dialysis session.
Species susceptibility: C. albicans maintains excellent fluconazole susceptibility (100% in recent surveillance) 6, while C. glabrata shows decreasing susceptibility over time and requires alternative agents 1, 6.
Monitoring: While generally well-tolerated, transient transaminase elevations occur in approximately 1% of patients 2. This is typically mild and self-limited but warrants baseline and follow-up liver function tests in patients receiving prolonged therapy.